Market research
SILK Silk Road Medical Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 20.75
- Dividend yield
- Not available
- Beta
- 1.54
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US82710M1009
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 20.75
- Dividend yield
- Not available
- Beta
- 1.54
About
About Silk Road Medical Inc
Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California. As of September 17, 2024, Silk Road Medical, Inc operates as a subsidiary of Boston Scientific Corporation.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SILK discussion.
5 years, 4 months ago
Silk Road Medical, Inc is currently in a long term downtrend where the price is trading 14.5% below its 200 day moving average.
From a valuation standpoint, the stock is 98.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 22.4.
Silk Road Medical, Inc's total revenue rose by 13.4% to $21M since the same quarter in the previous year.
Its net income has dropped by 102.1% to $-17M since the same quarter in the previous year.
Finally, its free cash flow fell by 166.1% to $-15M since the same quarter in the previous year.
Based on the above factors, Silk Road Medical, Inc gets an overall score of 2/5.